SciClone Pharma (SCLN) Reports Increase in Q3 Revs
Tweet
Share
E-mailGet Alerts SCLN Hot Sheet
Join SI Premium – FREE
SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) reports revenue for the third quarter of $22.8 million, compared to $17.2 million in Q309.
Cash, cash equivalents and investments were $53.3 million at September 30, 2010, compared with $31.8 at December 31, 2009.
Cash, cash equivalents and investments were $53.3 million at September 30, 2010, compared with $31.8 at December 31, 2009.
Create E-mail Alert Related Categories
Retail SalesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
